High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: A single center experience

Leukemia Research

Volumn 29, Issue 6, 2005, Pages 609-615

  Böhm, Alexandra ^a   Piribauer, Maria ^a   Wimazal, Friedrich ^a   Geissler, Klaus ^b   Gisslinger, Heinz ^a   Knöbl, Paul ^a   Jäger, Ulrich ^a   Fonatsch, Christa ^c   Kyrle, Paul A ^a   Valent, Peter ^a   Lechner, Klaus ^a   Sperr, Wolfgang R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c Clinical Institute of Medical   (Austria)

Author keywords

AML; Consolidation chemotherapy; High dose ARA C; Toxicity

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RASH; SIDE EFFECT;

EID: 20944444180     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.10.009     Document Type: Article

References (37)

1. R. Battista, R. Bassan, A. D'Emilio, P. Dragone, P. Viero, and E. Dini Short-term remission induction and consolidation therapy for adult acute myelogenous leukemia Hematol Oncol 9 1991 43 52
2. J.L. Harousseau, N. Milpied, J. Briere, B. Desablens, P.Y. Leprise, and N. Ifrah Double intensive consolidation chemotherapy in adult acute myeloid leukemia J Clin Oncol 9 1991 1432 1437
3. W. Hiddemann, and T. Buchner Current status and perspectives of therapy for acute myeloid leukemia Semin Hematol 38 2001 3 9
4. J.M. Rowe, and J.L. Liesveld Treatment and prognostic factors in acute myeloid leukaemia Baillieres Clin Haematol 9 1996 87 105
5. P.A. Cassileth, D.P. Harrington, J.D. Hines, M.M. Oken, J.J. Mazza, and P. McGlave Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia J Clin Oncol 6 1988 583 587
6. J.M. Bennett, J.W. Andersen, and P.A. Cassileth Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience Leuk Res 15 1991 222 223
7. C.D. Bloomfield Postremission therapy in acute myeloid leukemia J Clin Oncol 3 1985 1570 1572
8. H.T. Greinix, D. Nachbaur, O. Krieger, M. Eibl, P. Knobl, and P. Kalhs Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry Br J Haematol 117 2002 914 923
9. R.A. Zittoun, F. Mandelli, R. Willemze, T. de Witte, B. Labar, and L. Resegotti Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukaemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups N Engl J Med 332 1995 217 223
10. P.A. Cassileth, E. Lynch, J.D. Hines, M.M. Oken, J.J. Mazza, and J.M. Bennett Varying intensity of postremission therapy in acute myeloid leukemia Blood 79 1992 1924 1930
11. E.H. Estey Therapeutic options for acute myelogenous leukemia Cancer 92 2001 1059 1073
12. R. Zittoun, V. Liso, F. Mandelli, B. Rotoli, T. de Witte, and C. Gattringer Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group Leukemia 6 1992 76 77
13. R. Willemze, U. Jager, U. Jehn, P. Stryckmans, J. Bury, and S. Suciu Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study Eur J Cancer Clin Oncol 24 1988 1721 1725
14. R. Stasi, A. Venditti, G. Del Poeta, G. Aronica, E. Abruzzese, and F. Pisani High-dose chemotherapy in adult acute myeloid leukemia: rationale and results Leuk Res 20 1996 535 549
15. G. Schiller, J. Gajewski, M. Territo, S. Nimer, M. Lee, and T. Belin Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia Blood 80 1992 2977 2982
16. R.J. Mayer, R.B. Davis, C.A. Schiffer, D.T. Berg, B.L. Powell, and P. Schulman Intensive postremission chemotherapy in adults with acute myeloid leukaemia. Cancer and Leukemia Group B N Engl J Med 331 1994 896 903
17. A.M. Tsimberidou, N. Stavroyianni, N. Viniou, M. Papaioannou, M. Tiniakou, T. Marinakis The Hellenic Cooperative Group Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia Cancer 97 2003 1721 1731
18. S. Palmieri, L. Sebastio, G. Mele, M. Annunziata, S. Annunziata, and C. Copia High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21) Leuk Res 26 2002 539 543
19. E. Archimbaud, O.G. Ottmann, J.A. Yin, K. Lechner, H. Dombret, and M.A. Sanz A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia Blood 94 1999 3694 3701
20. J.M. Bennett, D. Catovsky, M.T. Daniel, G. Flandrin, D.A. Galton, and H.R. Gralnick Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group Br J Haematol 33 1976 451 458
21. J.M. Bennett, D. Catovsky, M.T. Daniel, G. Flandrin, D.A. Galton, and H.R. Gralnick Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group Ann Intern Med 103 1985 620 625
22. K. Mrozek, K. Heinonen, A. de la Chapelle, and C.D. Bloomfield Clinical significance of cytogenetics in acute myeloid leukemia Semin Oncol 24 1997 17 31
23. M.L. Slovak, K.J. Kopecky, P.A. Cassileth, D.H. Harrington, K.S. Theil, and A. Mohamed Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 2000 4075 4083
24. C.D. Bloomfield, D. Lawrence, J.C. Byrd, A. Carroll, M.J. Pettenati, and R. Tantravahi Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 1998 4173 4179
25. J.F. Bishop, R.M. Lowenthal, D. Joshua, J.P. Matthews, D. Todd, and R. Cobcroft Etoposide in acute nonlymphocytic leukaemia. Australian Leukemia Study Group Blood 75 1990 27 32
26. C.A. Schiffer, K.C. Anderson, C.L. Bennett, S. Bernstein, L.S. Elting, M. Goldsmith American Society of Clinical Oncology Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J Clin Oncol 15 2001 1519 1538
27. B.D. Cheson, P.A. Cassileth, D.R. Head, C.A. Schiffer, J.M. Bennett, and C.D. Bloomfield Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia J Clin Oncol 8 1990 813 819
28. J.C. Byrd, A.S. Ruppert, K. Mrozek, A.J. Carroll, C.G. Edwards, and D.C. Arthur Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461 J Clin Oncol 15 2004 1087 1094
29. J. Delaunay, N. Vey, T. Leblanc, P. Fenaux, F. Rigal-Huguet, F. Witz French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucemies Aigues Myeoblastiques; Leucemies Aigues Myeoblastiques de l'Enfant; Acute Leukemia French Association; Bordeaux-Grenoble-Marseille-Toulouse cooperative groups Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup Blood 102 2003 462 469
30. J.C. Byrd, R.K. Dodge, A. Carroll, M.R. Baer, C. Edwards, and J. Stamberg Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered J Clin Oncol 17 1999 3767 3775
31. T. Büchner, W. Hiddemann, W. Berdel, B. Wormann, C. Schoch, and H. Loffler Acute myeloid leukemia: treatment over 60 Rev Clin Exp Hematol 6 2002 46 59
32. W.R. Sperr, A.W. Hauswirth, F. Wimazal, P. Knobl, K. Geissler, and P. Valent Treatment concepts for elderly patients with acute myeloid leukemia Wien Klin Wochenschr 115 2003 505 514
33. W.J. Rombouts, B. Lowenberg, W.L. van Putten, and R.E. Ploemacher Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene Leukemia 15 2001 1046 1053
34. I. Moreno, G. Martin, P. Bolufer, E. Barragan, E. Rueda, and J. Roman Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia Haematologica 88 2003 19 24
35. P.D. Kottaridis, R.E. Gale, M.E. Frew, G. Harrison, S.E. Langabeer, and A.A. Belton The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 2001 1752 1759
36. E. Kimby, P. Nygren, B. Glimelius SBU-group Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in acute myeloid leukaemia Acta Oncol 40 2001 231 252
37. 2 on days 1, 3 and 5) Clin Cancer Res 10 2004 3965 3971